New Delhi: American multinational corporation Johnson and Johnson's single-dose COVID-19 vaccine 'Janssen' has been granted Emergency Use Authorization (EUA) in India. Union Health Minister Mansukh Mandaviya took to Twitter to inform that US pharmaceutical's single-dose COVID19 vaccine has been given emergency use approval. "India expands its vaccine basket! Johnson and Johnson's single-dose COVID-19 vaccine is given approval for Emergency Use in India. Now India has 5 EUA vaccines. This will further boost our nation's collective fight against COVID-19," Mandaviya tweeted.
Earlier, on Friday the US firm had informed that it has applied for an Emergency Use Authorization (EUA) of its single-dose vaccine 'Janssen' to the Government of India, adding it's an important milestone that paves the way to bringing the single-dose COVID-19 vaccine to the people of India, and the world, through a partnership with Biological E. Limited.
Read: Johnson & Johnson applies for emergency use of its single-dose COVID vaccine in India
The US pharma stated that the EUA submission is based on topline efficacy and safety data from the Phase 3 clinical trial, adding that their vaccine is 85 percent effective in preventing severe disease across all regions, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.
India has already crossed a significant milestone of having administered 50 crore vaccine doses under a nationwide vaccination drive. With 49,55,138 vaccinations in the last 24 hours, India has so far administered a total of 50,10,09,609 doses.
